KRAS and non-small cell lung carcinoma: Non-V600 BRAF mutant NSCLC tumors co-exist with mutations of the MAPK pathway signaling proteins, such as KRAS, but also frequently with loss of function (LoF) mutations in tumor suppressor genes involved in cellular processes such as metabolism (STK11) and oxidative stress response (KEAP1).